1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company Profiles
6.1. AdAlta Limited
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Aeolus Pharma
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Allinky Biopharma
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. AnaMar AB
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Apceth Biopharma
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Asahi Kasei Pharma Corporation
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. aTyr Pharma
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Avalyn Pharma
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. BerGenBio ASA
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Biogen
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Bioneer Corp
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Blade Therapeutics, Inc.
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Boehringer Ingelheim
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT Kadmon Corporation, LLC
6.14. BreStem Therapeutics
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. Capstone Therapeutics Corp.
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.16. Celdara Medical
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.17. Celgene
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.18. Chiesi Farmaceutici
6.18.1. Introduction
6.18.2. Financials
6.18.3. Products and Services
6.18.4. SWOT
6.19. Cynata
6.19.1. Introduction
6.19.2. Financials
6.19.3. Products and Services
6.19.4. SWOT
6.20. FibroGen, Inc.
6.20.1. Introduction
6.20.2. Financials
6.20.3. Products and Services
6.20.4. SWOT
6.21. FibroStatin
6.21.1. Introduction
6.21.2. Financials
6.21.3. Products and Services
6.21.4. SWOT
6.22. Galapagos NV
6.22.1. Introduction
6.22.2. Financials
6.22.3. Products and Services
6.22.4. SWOT
6.23. Galectin Therapeutics
6.23.1. Introduction
6.23.2. Financials
6.23.3. Products and Services
6.23.4. SWOT
6.24. Galecto Biotech
6.24.1. Introduction
6.24.2. Financials
6.24.3. Products and Services
6.24.4. SWOT
6.25. Genkyotex
6.25.1. Introduction
6.25.2. Financials
6.25.3. Products and Services
6.25.4. SWOT
6.26. Gilead Sciences
6.26.1. Introduction
6.26.2. Financials
6.26.3. Products and Services
6.26.4. SWOT
6.27. HEC Pharm
6.27.1. Introduction
6.27.2. Financials
6.27.3. Products and Services
6.27.4. SWOT
6.28. iBio Inc.
6.28.1. Introduction
6.28.2. Financials
6.28.3. Products and Services
6.28.4. SWOT
6.29. Inventiva Pharma
6.29.1. Introduction
6.29.2. Financials
6.29.3. Products and Services
6.29.4. SWOT
6.30. Kadmon Corporation, LLC
6.30.1. Introduction
6.30.2. Financials
6.30.3. Products and Services
6.30.4. SWOT
6.31. Lung Therapeutics
6.31.1. Introduction
6.31.2. Financials
6.31.3. Products and Services
6.31.4. SWOT
6.32. MediciNova, Inc.
6.32.1. Introduction
6.32.2. Financials
6.32.3. Products and Services
6.32.4. SWOT
6.33. Merck
6.33.1. Introduction
6.33.2. Financials
6.33.3. Products and Services
6.33.4. SWOT
6.34. Mission Therapeutics
6.34.1. Introduction
6.34.2. Financials
6.34.3. Products and Services
6.34.4. SWOT
6.35. NBHL Ltd
6.35.1. Introduction
6.35.2. Financials
6.35.3. Products and Services
6.35.4. SWOT
6.36. Nitto BioPharma, Inc.
6.36.1. Introduction
6.36.2. Financials
6.36.3. Products and Services
6.36.4. SWOT
6.37. Nuformix
6.37.1. Introduction
6.37.2. Financials
6.37.3. Products and Services
6.37.4. SWOT
6.38. OliX Pharmaceuticals, Inc.
6.38.1. Introduction
6.38.2. Financials
6.38.3. Products and Services
6.38.4. SWOT
6.39. Patara Pharma, Inc.
6.39.1. Introduction
6.39.2. Financials
6.39.3. Products and Services
6.39.4. SWOT
6.40. Pharmaxis
6.40.1. Introduction
6.40.2. Financials
6.40.3. Products and Services
6.40.4. SWOT
6.41. Pliant Therapeutics, Inc.
6.41.1. Introduction
6.41.2. Financials
6.41.3. Products and Services
6.41.4. SWOT
6.42. Promedior, Inc.
6.42.1. Introduction
6.42.2. Financials
6.42.3. Products and Services
6.42.4. SWOT
6.43. Prometic Life Sciences Inc.
6.43.1. Introduction
6.43.2. Financials
6.43.3. Products and Services
6.43.4. SWOT
6.44. Proterris
6.44.1. Introduction
6.44.2. Financials
6.44.3. Products and Services
6.44.4. SWOT
6.45. Pulmatrix, Inc.
6.45.1. Introduction
6.45.2. Financials
6.45.3. Products and Services
6.45.4. SWOT
6.46. Reata Pharmaceuticals, Inc.
6.46.1. Introduction
6.46.2. Financials
6.46.3. Products and Services
6.46.4. SWOT
6.47. Redx Pharma Plc
6.47.1. Introduction
6.47.2. Financials
6.47.3. Products and Services
6.47.4. SWOT
6.48. Respira Therapeutics, Inc.
6.48.1. Introduction
6.48.2. Financials
6.48.3. Products and Services
6.48.4. SWOT
6.49. Reviva Pharmaceuticals Inc.
6.49.1. Introduction
6.49.2. Financials
6.49.3. Products and Services
6.49.4. SWOT
6.50. Ribomic
6.50.1. Introduction
6.50.2. Financials
6.50.3. Products and Services
6.50.4. SWOT
6.51. SAJE Pharma
6.51.1. Introduction
6.51.2. Financials
6.51.3. Products and Services
6.51.4. SWOT
6.52. Samumed, LLC
6.52.1. Introduction
6.52.2. Financials
6.52.3. Products and Services
6.52.4. SWOT
6.53. Sanofi
6.53.1. Introduction
6.53.2. Financials
6.53.3. Products and Services
6.53.4. SWOT
6.54. Segue Therapeutics, LLC
6.54.1. Introduction
6.54.2. Financials
6.54.3. Products and Services
6.54.4. SWOT
6.55. Sorrento Therapeutics, Inc
6.55.1. Introduction
6.55.2. Financials
6.55.3. Products and Services
6.55.4. SWOT
6.56. Synairgen plc
6.56.1. Introduction
6.56.2. Financials
6.56.3. Products and Services
6.56.4. SWOT
6.57. Therabron
6.57.1. Introduction
6.57.2. Financials
6.57.3. Products and Services
6.57.4. SWOT
6.58. Unity Biotechnology
6.58.1. Introduction
6.58.2. Financials
6.58.3. Products and Services
6.58.4. SWOT
6.59. Vero Biotech
6.59.1. Introduction
6.59.2. Financials
6.59.3. Products and Services
6.59.4. SWOT
6.60. Vicore Pharma
6.60.1. Introduction
6.60.2. Financials
6.60.3. Products and Services
6.60.4. SWOT
6.61. X-Rx, Inc.
6.61.1. Introduction
6.61.2. Financials
6.61.3. Products and Services
6.61.4. SWOT
6.62. Yuhan
6.62.1. Introduction
6.62.2. Financials
6.62.3. Products and Services
6.62.4. SWOT
6.63. ZAI Lab Limited
6.63.1. Introduction
6.63.2. Financials
6.63.3. Products and Services
6.63.4. SWOT
List of Tables
List of Figures